Description
IDE574 is an experimental drug currently being studied in clinical trials for various advanced solid tumors, including microsatellite-stable (MSS) colorectal cancer. It is being investigated to determine its safety, how the body processes it (pharmacokinetics), and if it shows early signs of effectiveness. The trials are in Phase 1, which means they primarily focus on safety and finding the right dose. In some trials, IDE574 is being tested alone (monotherapy), while in others, it's being combined with another drug called fulvestrant, particularly for breast cancer. The trials are actively recruiting participants.
Mechanism of Action
IDE574 is being studied as a potential treatment for certain cancers. The specific way it works (its mechanism of action) is still being investigated in clinical trials. It is designed to target processes involved in tumor growth and survival. The trials are evaluating its effects on different types of advanced solid tumors, including those with specific genetic characteristics like HER2 mutations or MSS status in colorectal cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.